Lipocine (NASDAQ:LPCN – Get Free Report) posted its earnings results on Thursday. The specialty pharmaceutical company reported $0.33 earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.59, Zacks reports.
Lipocine Price Performance
Shares of NASDAQ:LPCN opened at $3.21 on Thursday. The firm has a fifty day moving average price of $4.01 and a two-hundred day moving average price of $4.53. The company has a market cap of $17.17 million, a price-to-earnings ratio of -4.22 and a beta of 1.42. Lipocine has a one year low of $2.91 and a one year high of $11.79.
Analysts Set New Price Targets
Separately, StockNews.com began coverage on Lipocine in a research report on Thursday, March 6th. They issued a “hold” rating for the company.
About Lipocine
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Featured Articles
- Five stocks we like better than Lipocine
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Gold Rally vs. Oil Surge: Where Investors Are Betting Next
- What is Forex and How Does it Work?
- Intel Stock Surges on New CEO – The Real Story Runs Deeper
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Market Overreacts, But Guidewire’s Growth Story Remains Strong
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
